Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 “multi-points priming” mechanisms in vitro and in vivo

Fig. 2

NCTD inhibits tumor lymphangiogenesis and lymphatic micrometastasis of the in-situ colonic xenografts by immunohistochemistry in vivo. a The expression of CK-20, LYVE-1 and D2-40 protein products of the in-situ colonic xenografts of each group (SABC, magnification × 200); NC, negative control, with only IgG to rule out the non-specific HRP-activated signal. b The LMVD of the in-situ colonic xenografts of each group. The lowest LMVD, with no or weaken expression of CK20, LYVE-1 or D2-40s in NC group (P < 0.001, vs. control, Sorafenib, NCTD or NCTD + Sorafenib group); the lower LMVD, with weaken expression of CK20, LYVE-1 or D2-40 and few, thin and destroyed microvessels in Sorafenib, NCTD or NCTD + Sorafenib group as compared with control group (all *P < 0.05). Of them, the LMVD of NCTD + Sorafenib group was lowest (#P < 0.001, vs. Sorafenib or NCTD group)

Back to article page